During the last session, Repligen Corp (NASDAQ:RGEN)’s traded shares were 0.75 million, with the beta value of the company hitting 1.16. At the end of the trading day, the stock’s price was $130.00, reflecting an intraday loss of -1.59% or -$2.1. The 52-week high for the RGEN share is $182.52, that puts it down -40.4 from that peak though still a striking 20.8% gain since the share price plummeted to a 52-week low of $102.96. The company’s market capitalization is $7.30B, and the average intraday trading volume over the past 10 days was 1.15 million shares, and the average trade volume was 764.20K shares over the past three months.
Repligen Corp (RGEN) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.70. RGEN has a Sell rating from 1 analyst(s) out of 9 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.35.
Repligen Corp (NASDAQ:RGEN) trade information
Repligen Corp (RGEN) registered a -1.59% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -1.59% in intraday trading to $130.00, hitting a weekly high. The stock’s 5-day price performance is 12.86%, and it has moved by -10.27% in 30 days. Based on these gigs, the overall price performance for the year is -20.81%. The short interest in Repligen Corp (NASDAQ:RGEN) is 3.54 million shares and it means that shorts have 4.85 day(s) to cover.
The consensus price target of analysts on Wall Street is $220, which implies an increase of 40.91% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $220 and $220 respectively. As a result, RGEN is trading at a discount of -69.23% off the target high and -69.23% off the low.
Repligen Corp (RGEN) estimates and forecasts
In the rating firms’ projections, revenue will increase 10.46% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 163.75M as predicted by 18 analyst(s). Meanwhile, a consensus of 16 analyst(s) estimates revenue growth to 173.18M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 151.35M and 154.07M respectively. In this case, analysts expect current quarter sales to grow by 8.20% and then jump by 12.40% in the coming quarter.
RGEN Dividends
Repligen Corp is due to release its next quarterly earnings on 2025-Feb-19. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Repligen Corp (NASDAQ:RGEN)’s Major holders
Repligen Corp insiders own 6.44% of total outstanding shares while institutional holders control 103.39%, with the float percentage being 110.51%. BLACKROCK INC. is the largest shareholder of the company, while 592.0 institutions own stock in it. As of 2024-06-30, the company held over 7.57 million shares (or 13.5432% of all shares), a total value of $954.08 million in shares.
The next largest institutional holding, with 5.07 million shares, is of VANGUARD GROUP INC’s that is approximately 9.0659% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $638.67 million.
Also, the Mutual Funds coming in first place with the largest holdings of Repligen Corp (RGEN) shares are iShares Trust-iShares Core S&P Mid-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . Data provided on Mar 31, 2025 indicates that iShares Trust-iShares Core S&P Mid-Cap ETF owns about 1.7 shares. This amounts to just over 3.03 percent of the company’s overall shares, with a $221.25 million market value. The same data shows that the other fund manager holds slightly less at 1.67, or about 2.97% of the stock, which is worth about $216.97 million.
